FAUCI CHANGED METRICS OF DRUG TRIAL TO MAKE OUTCOME LOOK BETTER

MSN:

Instead of counting how many people taking the drug were kept alive on ventilators or died, among other measures, the National Institute of Allergy and Infectious Diseases (Fauci’s outfit) said it would judge the drug primarily on a different outcome: how long it took surviving patients to recover.

Government clinical trial investigators changed the primary metric for measuring the success of Gilead’s experimental drug remdesivir as a coronavirus treatment two weeks before Anthony S. Fauci’s announcement that the drug would be the new “standard of care.”

Death and other negative outcomes were moved to secondary measure status: They would still be tracked, but they would no longer be the key measure of remdesivir’s performance. The switch — which specialists said is unusual in major clinical trials but not unheard of — was publicly disclosed on the government’s clinicaltrials.gov website on April 16 but did not receive much attention at the time. 

Read more at MSN.com

Buy on Amazon!

Advertisements